Sun Pharmaceutical Industries Ltd has fixed Tuesday, 07 July 2026, as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share for the financial year 2025-26. The payment of this dividend, if approved by shareholders, will be made on or before Friday, 07 August 2026. The dividend distribution is subject to tax deduction at source (TDS) at applicable rates, with shareholders required to submit necessary documents by the record date to ensure the correct TDS rate is applied.

The company announced that its 34th Annual General Meeting (AGM) will be held on Friday, 31 July 2026, at 4:00 p.m. IST via Video Conferencing. The Notice convening the AGM and the Annual Report for FY 2025-26 will be dispatched to shareholders in compliance with statutory requirements. Shareholders have been advised to update their contact details with their Depository Participants or the company's Registrar and Transfer Agent to ensure timely delivery of documents and dividend credits.

Key AGM and Dividend Details

The company has provided guidance on TDS and the document submission process via its official website and a QR code. Anoop Deshpande, Company Secretary and Compliance Officer, signed the intimation on 11 June 2026.

Sun Pharmaceutical Industries Ltd. recorded a notable block trade on the National Stock Exchange (NSE), with the transaction valued at Rs. 19.03 crores. The trade involved approximately 106,240 shares executed at a price of Rs. 1790.90 per share.

Block Trade Details

The following table summarizes the key parameters of the block trade recorded on the NSE:

Block trades are large, privately negotiated securities transactions that are executed outside of the open market to minimize the impact on the prevailing market price. Such trades are typically carried out by institutional investors and represent a significant volume of shares transacted in a single deal.